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Abstract
Aim:  To evaluate the effects of two formulations, Cissus quadrangularis-only and a Cissus
quadrangularis/Irvingia gabonensis combination, on weight loss in overweight and obese human
subjects.
Methods: The study was a 10 week randomized, double-blind, placebo-controlled design involving
72 obese or overweight participants (45.8% male; 54.2% female; ages 21–44; mean age = 29.3). The
participants were randomly divided into three equal (n = 24) groups: placebo, Cissus quadrangularis-
only, and Cissus quadrangularis/Irvingia gabonensis combination. Capsules containing the placebo or
active formulations were administered twice daily before meals; no major dietary changes nor
exercises were suggested during the study. A total of six anthropomorphic and serological
measurements (body weight, body fat, waist size; total plasma cholesterol, LDL cholesterol, fasting
blood glucose level) were taken at baseline and at 4, 8 and 10 weeks.
Results: Compared to the placebo group, the two active groups showed a statistically significant
difference on all six variables by week 10. The magnitude of the differences was noticeable by week
4 and continued to increase over the trial period.
Conclusion: Although the Cissus quadrangularis-only group showed significant reductions on all
variables compared to the placebo group, the Cissus quadrangularis/Irvingia gabonensis combination
resulted in even larger reductions. This apparently synergistic formulation should prove helpful in
the management of obesity and its related complications.
Background
The percentage of persons whose body weight is consider-
ably greater than ideal continues to rapidly increase, par-
ticularly in the developed countries. As early as
1999–2000, approximately two-thirds of the U.S. adult
population was classified as overweight or obese [1].
Excess body weight is one of the most important risk fac-
tors for all-cause morbidity and mortality; i.e., the likeli-
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hood of developing such conditions as Type 2 diabetes,
heart disease, cancer, and osteoarthritis of weight-bearing
joints increases with body weight [2-4]. In addition to
individual pain and suffering, these conditions lead to
substantial economic costs in national healthcare budgets
[5].
Among the many factors responsible for overweight and
obesity is the continuing decline in physical activity [5,6].
hence the probability of compliance with conventional
weight-management programs, which often include
increasing energy expenditure via physical activity, is low.
It is not at all surprising to see the marketing of many new
dietary slimming aids aimed at satisfying the need for pal-
atable (as well as safe, effective, and therapeutic) options.
In accord with this approach are numerous investigations
of the effectiveness of medicinal plants as natural supple-
ments in reducing body weight, e.g., Cissus quadrangularis
(Linn) and Irvingia gabonensis (Aubry-Lecomte ex
O'Rorke).
Cissus quadrangularis (CQ), a succulent vine native to West
Africa and Southeast Asia, has been used in traditional
African and Ayurvedic medicine for more than a century.
Although some studies [7-10] have examined other uses
of CQ, its role in fighting obesity and symptoms of meta-
bolic syndrome has attracted interest in other parts of the
world [11-14]. The unique chemical constituents of
CQ–novel flavonoids and indanes, as well as phytosterols
and keto-steroids–have shown promise as powerful and
efficient antioxidants [13,14]. They also appear efficient
for lipase and amylase inhibition, thereby providing a
mechanism for weight loss via reduced oxidative stress,
dietary fat, and carbohydrate blocking.
Researchers and therapy formulation experts have also
tried to improve the properties of CQ by combining it
with different ingredients (cf. Cylaris™, which contains
chromium, selenium, green tea extract, etc.) Another
potentially synergistic substance–Irvingia gabonensis
(IG)–belongs to the Irvingiaceae family. The Irvingia tree,
commonly known as bush mango, dikanut or African
mango [15], is indigenous to West Africa. Although the
flesh of the IG fruit is widely consumed, its most impor-
tant part is the kernel which (in its fresh or dried form) is
used to add flavouring and consistency to many dishes
[16].
IG contains 50% fat, 26.4% total carbohydrate, 2.3% ash,
7.5% crude protein, and 14% fibre [16]. The high soluble
fibre content effects the lowering of plasma cholesterol,
triglycerides, and glucose concentrations. More impor-
tantly, the glycoproteins in the IG seeds seem to inhibit
hydrolase enzymes by blocking the active sites or altering
enzyme configuration. Recent investigation of the α-amy-
lase inhibitory activity provides a mechanistic hypothesis
for the numerous studies supporting IG's anti-diabetic
potential via its ability to reduce fasting blood glucose lev-
els [17].
In addition to their anti-diabetic activity, IG seeds have
shown promise as an anti-obesity agent. A 2005 rand-
omized, double-blind, placebo-controlled study reported
significant differences between the IG treatment and pla-
cebo groups in weight and fat loss, as well as reductions in
hip and waist circumference [18].
Alpha-amylase inhibitors are drug-design targets in the
development of compounds for the treatment of diabetes,
obesity and hyperlipaemia [19]. Although much research
has focused on glycosidase inhibitors to control hypergly-
cemia, many forms of starch are digested as rapidly as glu-
cose absorption [20,21]. Slowing the digestion and
breakdown of starch has beneficial effects on insulin
resistance and glycemic index control in people with obes-
ity-related diabetes [20,22].
The present study was primarily designed to test the effi-
cacy of a combination of these two extraordinary
plants–Cissus quadrangularis and Irvingia gabonensis–in the




Seventy-two obese or overweight subjects were recruited
for the 10-week study. Based on physical examination and
laboratory screening tests, all diabetics as well as pregnant
and lactating women were excluded. None of the partici-
pants took any weight-reducing medication nor followed
any specific diet for the duration of the trial period.
Of the 72 subjects, 33 (45.8%) were male and 39 (54.2%)
were female. The mean BMI was > 26 kg/m, and the age
range was 21–44 (mean age = 29.3).
The purpose, nature and potential risks of the study were
explained to the patients, and all gave their written
informed consent before participation. The Cameroon
National Ethics Committee approved the protocol. The
study was conducted in accordance with the Helsinki Dec-
laration (1983 version).
Study design/Intervention
The study was a randomized, double-blind, placebo-con-
trolled design. The participants were randomly divided
into three equal groups (n = 24): placebo; CQ-only
extract, and CQ-IG combination. The placebo (250 mg)
or active formulations (150 mg CQ and 250 mg CQ-IG)
were administered twice daily before meals with 8–10 oz.Lipids in Health and Disease 2008, 7:12 http://www.lipidworld.com/content/7/1/12
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of water. Since the capsules were identical in shape, colour
and appearance, neither the participants nor the research-
ers knew which treatment was administered. The CQ and
IG were proprietary extracts standardized to 2.5% keto-
steroids for CQ (CQR-300) and 7% albumins for IG
(IGOB131). All testing materials were supplied by Gate-
way Health Alliances, Inc., Fairfield, California, USA.
The 72 subjects were examined once a week during the 10-
week study period, and their body weight, percent body
fat, and waist circumference were recorded. Fasting blood
samples were taken at baseline and at 4, 8, and 10 weeks.
In addition to these physiological measurements, the
patients' subjective impressions of their well-being (e.g.,
increased/decreased appetite, dizziness, gastrointestinal
pains, etc.) were solicited and recorded at every visit.
Although no major dietary changes or exercises were sug-
gested, the subjects were queried re their physical activity
and food intake.
Anthropometric measurements
Body weight, percent body fat, and waist circumference
were assessed at each visit with a Tanita™ BC-418 Segmen-
tal Body Composition Analyzer/Scale that uses bio-electri-
cal impedance analysis for body composition analysis.
Height was measured with a Harpended™ stadiometer,
which measures the length of curved line staffage to the
nearest 0.5 cm. Participants (12 hour fasted) were encour-
aged to wear light clothing before measurements were
taken. The waist circumference was measured by soft,
non-stretchable plastic tape on the narrowest and widest
parts of the trunk.
Serological/Laboratory methods
Blood samples were collected into heparinized tubes after
a 12-hour overnight fast at the beginning of the study and
after 4, 8, and 10 weeks of treatment. The concentrations
of total cholesterol, LDL cholesterol, and fasting blood
glucose in plasma were measured using commercial diag-
nostic kits from SIGMA Diagnostics, St. Louis, Missouri
USA.
Statistical Analysis
The data for each parameter was summarized (n, mean,
and standard deviation) for Week 0 (Initial) and Weeks 4,
8, and 10 and for the intra-group percent differences (Ini-
tial vs. Week 4, Week 8, and Week 10). The percent change
from baseline was tested for differences using the Mixed
Effects Model, which is a flexible tool for analyzing longi-
tudinal and repeated treatments. For each parameter, sev-
eral measurements were made. This continuous
measurement over a specified period justifies the sample
size used for each group.
Results
Anthropomorphic characteristics (body weight, body fat, 
waist size)
As shown in Tables 1, 2, and 3, the two treatment (vs. pla-
cebo) groups showed a noticeable decrease in these three
variables by week 4 and maintained–indeed, significantly
increased–the magnitude of the differences throughout
the 10-week trial period. By week 10, the differences in
measures of body weight, body fat, and waist size between
the CQ-IG combination group vs. the CQ-only and pla-
cebo groups were all statistically significant.
Body weight (Table 1)
Although the placebo group showed no change in body
weight, the CQ-IG group lost 4 kg (4.0%) after just 4
weeks of treatment. To translate the difference in amounts
lost to final outcomes, the 10-week mean body weight of
the CQ-IG group was 88.0 kg vs 96.0 kg for the placebo
group (p < 0.0001) and 90.2 kg for the CQ group (p <
0.001). In terms of intra-group mean % change from base-
line to 10 weeks, the placebo, CQ and CQ-IG combo
groups lost 2.1%, 8.8% (p < 0.05), and 11.9% (p < 0.05),
respectively.
Body fat (Table 2)
As with body weight, the placebo group showed no signif-
icant change in %-body fat after 4 weeks whereas the CQ-
IG group lost 3.2% body fat (i.e., a 9.11% reduction). To
translate the differences in amount lost to final outcomes,
the 10-week mean %-body fat of the CQ-IG group was
Table 1: Body weight: effectiveness of treatments
Body weight (mean kg) Weight change (%)
Initial 4 weeks 8 weeks 10 weeks 4 Weeks-Initial 8 Weeks-Initial 10 Weeks-Initial
Placebo 98.05 ± 12.30 98.76 ± 8.20 96.74 ± 10.60 95.99 ± 15.20 0.72 -1.33 -2.10
CQ 98.92 ± 10.60 95.77 ± 12.32a 91.47 ± 8.69a 90.19 ± 7.60b -3.19 -7.53† -8.82†
CQ-IG 99.79 ± 13.50 95.77 ± 7.40 90.91 ± 5.72b * 87.95 ± 3.17c ** -4.02† -8.90† -11.86†
ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysisLipids in Health and Disease 2008, 7:12 http://www.lipidworld.com/content/7/1/12
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28.5% vs 32.0% for the placebo group (p < 0.05) and
28.2% for the CQ group (p < 0.05). In terms of intra-
group mean % change from baseline to 10 weeks, the pla-
cebo, CQ and CQ-IG combo groups lost 4.0%, 14.6% (p
< 0.05), and 20.0% (p < 0.001), respectively.
Waist size (Table 3)
Waist circumference is one of the most important deter-
minants in the diagnosis of obesity and metabolic syn-
drome. Once again, whereas the placebo group showed a
minimal decrease (0.6 cm or .6%), the CQ-IG group lost
6.0 cm (5.8%) after 4 weeks. By week 10, the reduction in
waist size was 1.0 cm for the placebo group vs. 21.9 cm for
the CQ-IG group.
To translate the difference in amounts lost to final out-
comes, the 10-week mean waist size (cm) of the CQ-IG
group was 82.4 cm vs 101.4 cm for the placebo group (p
< 0.0001) and 91.2 cm for the CQ group (p < 0.001). In
terms of intra-group mean % change from baseline to 10
weeks, the placebo, CQ and CQ-IG combo groups lost
1.0%, 8.6% (p < 0.05), and 21.0% (p < 0.05), respectively.
Serological characteristics (total cholesterol, LDL 
cholesterol, fasting blood glucose)
As shown in Tables 4, 5, and 6, the treatment (vs. placebo)
groups showed a noticeable decrease in these three varia-
bles by week 4. As was the case with the three anthropo-
morphic variables, the magnitude of the losses increased
significantly over the duration of the 10-week trial period.
Plasma total cholesterol level (Table 4)
Although the placebo group showed a small, short-lived
decrease (5.8 mg/dL) by week 4, the reduction for the CQ-
IG group was 44.8 mg/dL (29.2%). To translate the differ-
ence in amounts decreased to final outcomes, the 10-week
mean total cholesterol level of the CQ-IG group was 85.3
mg/dL vs 149.5 mg/dL for the placebo group (p < 0.001)
and 110.2 mg/dL for the CQ group (p < 0.0001). In terms
of intra-group mean % change from baseline to 10 weeks,
the placebo group increased by 2.2%; the CQ and CQ-IG
combo group decreased by 27.0% (p < 0.05) and 44.3%
(p < 0.05), respectively.
Plasma LDL cholesterol level (Table 5)
In contrast to the small (3.3 mg/dL) increase in LDL
shown by the placebo group by week 4, the CQ-IG group
showed a 25.8 mg/dL (30.0%) decrease. To translate the
difference in amounts decreased to final outcomes, the
10-week mean LDL cholesterol level of the CQ-IG group
was 44.2 mg/dL vs 73.9 mg/dL for the placebo group (p <
0.05) and 64.2 mg/dL for the CQ group (p < 0.001). In
terms of intra-group mean % change from baseline to 10
weeks, the placebo, CQ and CQ-IG combo groups
decreased by 3.0%, 20.2% (p < 0.001), and 48.7% (p <
0.001), respectively.
Table 2: Body fat: effectiveness of treatments
Body fat (mean %) Fat reduction (%)
Initial 4 weeks 8 weeks 10 weeks 4 Weeks-Initial 8 Weeks-Initial 10 Weeks-Initial
Placebo 33.32 ± 7.60 32.37 ± 12.86 32.31 ± 10.91 32.00 ± 14.63 -2.85 -3.33 -3.97
CQ 33.07 ± 10.26 30.81 ± 5.92 29.42 ± 5.49 28.23 ± 6.12a -6.83 -11.05† -14.63†
CQ-IG 35.66 ± 12.27 32.41 ± 7.91 29.53 ± 5.15 28.51 ± 4.17a *- 9 . 1 1 † -17.19† -20.06‡
ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis
Table 3: Waist size: effectiveness of treatments
Waist (mean cm) Waist Change (%)
Initial 4 weeks 8 weeks 10 weeks 4 Weeks-Initial 8 Weeks-Initial 10 Weeks-Initial
Placebo 102.40 ± 16.26 101.82 ± 12.21 101.76 ± 13.30 101.37 ± 16.55 -0.56 -0.63 -1.00
CQ 99.83 ± 13.38 97.10 ± 18.57 93.81 ± 10.70a 91.20 ± 7.6b -2.73 -6.03† -8.64†
CQ-IG 104.30 ± 23.10 98.28 ± 17.41 96.00 ± 12.20b ** 82.42 ± 3.88c ** -5.77† -7.96† -20.98†
ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysisLipids in Health and Disease 2008, 7:12 http://www.lipidworld.com/content/7/1/12
Page 5 of 7
(page number not for citation purposes)
Fasting blood glucose levels (Table 6)
In contrast to the small (1.1 mg/dL) decrease in blood glu-
cose level shown by the placebo group by week 4, the CQ-
IG group showed a 19.4 mg/dL decrease (22.1%). To
translate the difference in amounts decreased to final out-
comes, the 10-week mean blood glucose level of the CQ-
IG group was 60.1 mg/dL vs 77.3 mg/dL for the placebo
group (p < 0.001) and 68.4 mg/dL for the CQ group (p <
0.001). In terms of intra-group mean % change from base-
line to 10 weeks, the placebo, CQ and CQ-IG combo
groups decreased by 2.6%, 14.8% (p < 0.05), and 31.4%
(p < 0.001), respectively.
Adverse events
Adverse events with an incidence >3 included headache
(4), lack of sleep (4), and gas (5). Since the incidence of
all reported side effects was observed in the placebo group
as well as in the treatment groups, it is probably safe to
conclude that the CQ-IG formulation had few, if any, neg-
ative side effects.
Discussion
It is generally accepted that slowing the spread of obesity
(and its concomitant complications) requires a multi-
dimensional approach including, perhaps, the use of
novel treatments involving control at different levels; e.g.
lipid metabolism, carbohydrate metabolism, satiety, etc.
The present study showed that a therapy comprising a
combination of different active substances had considera-
ble potential.
In previous studies [12,13], the CQ-only formulation
showed beneficial effects on weight as well as on parame-
ters of metabolic syndrome. Oxidative stress resulting
from obesity and metabolic syndrome seems to be gain-
ing ground as a major factor in the development and pro-
gression of these conditions. When calorie intake exceeds
energy expenditure, the substrate-induced increase in cit-
ric acid cycle activity generates an excess of mitochondrial
NADH and reactive oxygen species [23].
Independent of the above, escalation of adipose tissue
effects an increase in the secretion of inflammatory
cytokines, interleukin-6, and tumor necrosis factor-alpha,
which could result in increased circulating levels of C-
reactive protein, inflammation, and cardiovascular dis-
ease [24]. Reducing the oxidative stress by CQ and/or IG
[independently submitted for publication] could improve
insulin sensitivity, inflammation, body-mass index, cardi-
ovascular disease and related conditions.
Our results showed that the combination of CQ and IG
had a synergistic effect on the reduction of total choles-
terol, LDL-cholesterol, and fasting blood glucose when
compared to CQ-only, thus creating a better anti-athero-
genic agent. The efficacy of CQ has been linked to its con-
tent of various steroidal principles, a novel flavonoid (3-
Table 4: Plasma total cholesterol level: effectiveness of treatments
Total cholesterol (mean mg/dL) Change (%)
Initial 4 weeks 8 weeks 10 weeks 4 Weeks-Initial 8 Weeks-Initial 10 Weeks-
Initial
Placebo 146.20 ± 38.14 140.40 ± 11.11 150.06 ± 13.20 149.47 ± 19.16 -3.965 2.64 2.23
CQ 150.34 ± 21.24 122.31 ± 15.56b 116.40 ± 17.30b 110.21 ± 9.34b -18.64† -22.57† -26.69†
CQ-IG 153.21 ± 20.21 108.45 ± 18.21b 
**
89.48 ± 10.66b *** 85.33 ± 7.80b *** -29.21† -41.59† -44.30†
ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysis
Table 5: Plasma LDL cholesterol level: effectiveness of treatments
LDL cholesterol (mean mg/dL) Change (%)
Initial 4 weeks 8 weeks 10 weeks 4 Weeks-Initial 8 Weeks-Initial 10 Weeks-Initial
Placebo 76.13 ± 8.02 79.47 ± 7.50 74.35 ± 9.02 73.87 ± 8.44 4.38 -2.34 -2.96
CQ 80.41 ± 8.30 66.30 ± 11.06b 63.69 ± 8.79b 64.20 ± 11.13b -17.55† -20.78‡ -20.16‡
CQ-IG 86.11 ± 7.82 60.30 ± 9.39b ** 57.28 ± 8.36b ** 44.18 ± 10.02a ** -29.96† -33.48‡ -48.69‡
ap < 0.05; bp < 0.001; cp < 0.0001 compared with Placebo
*p < 0.05; **p < 0.001; ***p < 0.0001 compared with CQ
†p < 0.05; ‡p < 0.001 compared with Initial; intra-group analysisLipids in Health and Disease 2008, 7:12 http://www.lipidworld.com/content/7/1/12
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O-alpha-L-rhamnopyranosylkaempferol) and stilbene (3-
(4-hydroxybenzylidene)-2-(2,5-dihydroxyphenyl)-1-(4-
hydroxyphenyl)indane-4,6-diol), as well as four known
structurally related flavonoids, and one stilbene [14].
These components also have the ability to inhibit certain
enzymes like alpha amylase, glucosidase and lipase
[11,14]. IG seeds, on the other hand, have been shown to
have hypocholesterolemic, hypoglycaemic, anti-amylase,
anti-lipase, and anti-oxidant properties [18,25].
A formulation comprising a combination of these two
plant materials suggests one distinct possibility in the
multi-dimensional management of obesity and its related
complications.
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